1018 ISS

CpG 1018 oligodeoxynucleotide adjuvant · Dynavax Technologies Corporation

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for 1018 ISS, covering 2010-01-29 to 2010-01-29. Get the full timeline:

Most recent: Clinical Trial Update: Study of Dynavax's 1018 ISS, Following Rituxan in Patients With B-Cell Follicular Lymphoma [Phase 2]